Drug Profile

VK 2735

Alternative Names: VK-2735

Latest Information Update: 17 Feb 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Viking Therapeutics
Class Antihyperglycaemics; Hepatoprotectants; Obesity therapies
Mechanism of Action Gastric inhibitory polypeptide receptor agonists; Glucagon-like peptide-1 receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase III Obesity
Phase I Non-alcoholic steatohepatitis
Preclinical Diabetes mellitus

Most Recent Events

11 Feb 2026 Viking Therapeutics completes an End-of-phase II meeting with US FDA for Obesity (SC)
11 Feb 2026 Viking Therapeutics completes an end-of-Phase II meeting with US FDA for Obesity (PO)
11 Feb 2026 Viking Therapeutics plans a phase III trial for Obesity (PO, Tablet) in third quarter of 2026

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com